Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $1.15 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 470.97% to $1.15 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.03 through Dec 2025, up 276.52% year-over-year, with the annual reading at $2.06 for FY2025, 279.13% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.15 at Theravance Biopharma, up from $0.07 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.15 in Q4 2025, with the low at -$1.24 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.22, with a median of -$0.26 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 154.55% in 2023, then soared 470.97% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.43 in 2021, then surged by 65.12% to -$0.15 in 2022, then fell by 13.33% to -$0.17 in 2023, then plummeted by 82.35% to -$0.31 in 2024, then skyrocketed by 470.97% to $1.15 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $1.15, $0.07, and $1.08 for Q4 2025, Q3 2025, and Q2 2025 respectively.